Tags

Type your tag names separated by a space and hit enter

Paget's disease of bone: an endocrine society clinical practice guideline.
J Clin Endocrinol Metab. 2014 Dec; 99(12):4408-22.JC

Abstract

OBJECTIVE

The aim of this guideline was to formulate practice guidelines for the diagnosis and treatment of Paget's disease of the bone.

PARTICIPANTS

The guideline was developed by an Endocrine Society-appointed Task Force of experts, a methodologist, and a medical writer.

EVIDENCE

This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe both the strength of recommendations and the quality of evidence.

CONSENSUS PROCESS

One group meeting, several conference calls, and e-mail communications enabled consensus. Committees and members of The Endocrine Society and the European Society of Endocrinology reviewed and commented on preliminary drafts of these guidelines. Two systematic reviews were conducted to summarize supporting evidence.

CONCLUSIONS

We recommend that plain radiographs be obtained of the pertinent regions of the skeleton in patients with suspected Paget's disease. If the diagnosis is confirmed, we suggest that a radionucleotide bone scan be done to determine the extent of the disease. After diagnosis of Paget's disease, we recommend measurement of serum total alkaline phosphatase or, when warranted, a more specific marker of bone formation or bone resorption to assess the response to treatment or evolution of the disease in untreated patients. We suggest treatment with a bisphosphonate for most patients with active Paget's disease who are at risk for future complications. We suggest a single 5-mg dose of iv zoledronate as the treatment of choice in patients who have no contraindication. In patients with monostotic disease who have a normal serum total alkaline phosphatase, we suggest that a specific marker of bone formation and bone resorption be measured, although these may still be normal. Serial radionuclide bone scans may determine the response to treatment if the markers are normal. We suggest that bisphosphonate treatment may be effective in preventing or slowing the progress of hearing loss and osteoarthritis in joints adjacent to Paget's disease and may reverse paraplegia associated with spinal Paget's disease. We suggest treatment with a bisphosphonate before surgery on pagetic bone.

Authors+Show Affiliations

John Wayne Cancer Institute at Providence St John's Health Center (F.R.S.), Santa Monica, California 90404; Michigan Bone and Mineral Clinic (H.G.B.), Detroit, Michigan 48236; Nottingham City Hospital (D.J.H.), Nottingham NG5 1PB, United Kingdom; Duke University and VA Medical Centers (K.W.L.), Durham, North Carolina 27710; Carolina's Center for Medical Excellence (K.W.L.), Cary, North Carolina 27518; Mayo Clinic (M.H.M.), Rochester, Minnesota 55905; University of Auckland (I.R.R.), Auckland 1023, New Zealand; and Columbia University College of Physicians & Surgeons (E.S.S.), New York, New York 10032.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Practice Guideline
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

25406796

Citation

Singer, Frederick R., et al. "Paget's Disease of Bone: an Endocrine Society Clinical Practice Guideline." The Journal of Clinical Endocrinology and Metabolism, vol. 99, no. 12, 2014, pp. 4408-22.
Singer FR, Bone HG, Hosking DJ, et al. Paget's disease of bone: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(12):4408-22.
Singer, F. R., Bone, H. G., Hosking, D. J., Lyles, K. W., Murad, M. H., Reid, I. R., & Siris, E. S. (2014). Paget's disease of bone: an endocrine society clinical practice guideline. The Journal of Clinical Endocrinology and Metabolism, 99(12), 4408-22. https://doi.org/10.1210/jc.2014-2910
Singer FR, et al. Paget's Disease of Bone: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2014;99(12):4408-22. PubMed PMID: 25406796.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Paget's disease of bone: an endocrine society clinical practice guideline. AU - Singer,Frederick R, AU - Bone,Henry G,3rd AU - Hosking,David J, AU - Lyles,Kenneth W, AU - Murad,Mohammad Hassan, AU - Reid,Ian R, AU - Siris,Ethel S, AU - ,, PY - 2014/11/20/entrez PY - 2014/11/20/pubmed PY - 2015/10/8/medline SP - 4408 EP - 22 JF - The Journal of clinical endocrinology and metabolism JO - J Clin Endocrinol Metab VL - 99 IS - 12 N2 - OBJECTIVE: The aim of this guideline was to formulate practice guidelines for the diagnosis and treatment of Paget's disease of the bone. PARTICIPANTS: The guideline was developed by an Endocrine Society-appointed Task Force of experts, a methodologist, and a medical writer. EVIDENCE: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe both the strength of recommendations and the quality of evidence. CONSENSUS PROCESS: One group meeting, several conference calls, and e-mail communications enabled consensus. Committees and members of The Endocrine Society and the European Society of Endocrinology reviewed and commented on preliminary drafts of these guidelines. Two systematic reviews were conducted to summarize supporting evidence. CONCLUSIONS: We recommend that plain radiographs be obtained of the pertinent regions of the skeleton in patients with suspected Paget's disease. If the diagnosis is confirmed, we suggest that a radionucleotide bone scan be done to determine the extent of the disease. After diagnosis of Paget's disease, we recommend measurement of serum total alkaline phosphatase or, when warranted, a more specific marker of bone formation or bone resorption to assess the response to treatment or evolution of the disease in untreated patients. We suggest treatment with a bisphosphonate for most patients with active Paget's disease who are at risk for future complications. We suggest a single 5-mg dose of iv zoledronate as the treatment of choice in patients who have no contraindication. In patients with monostotic disease who have a normal serum total alkaline phosphatase, we suggest that a specific marker of bone formation and bone resorption be measured, although these may still be normal. Serial radionuclide bone scans may determine the response to treatment if the markers are normal. We suggest that bisphosphonate treatment may be effective in preventing or slowing the progress of hearing loss and osteoarthritis in joints adjacent to Paget's disease and may reverse paraplegia associated with spinal Paget's disease. We suggest treatment with a bisphosphonate before surgery on pagetic bone. SN - 1945-7197 UR - https://www.unboundmedicine.com/medline/citation/25406796/Paget's_disease_of_bone:_an_endocrine_society_clinical_practice_guideline_ L2 - https://academic.oup.com/jcem/article-lookup/doi/10.1210/jc.2014-2910 DB - PRIME DP - Unbound Medicine ER -